Emerging RCTs and real-world data, together with complementary mechanisms of action, supported the use of GLP-1 receptor agonists for the prevention of myocardial infarction, heart failure, cardiomyopathy, and atherosclerosis in patients with T2DM (Table 2; Ussher and Drucker, 2023). The gene discussed is GLP1R; the disease is atherosclerosis.